In Fabry mice, Eliglustat administered in food generally produced significant net GL-3 reductions of 40–50% in evaluated visceral tissues and whole blood, with no difference observed in brain between treated and untreated mice. In the urinary readout study, Eliglustat reduced urine GL-3 concentration to about 50% that of untreated Fabry mice. In female C57BL/6J mice, Eliglustat at 150 mg/kg/day in chow for 19 days significantly increased bone parameters, including bone volume over total volume (BV/TV), compared with normal chow controls. [2,3]
GL-3 reductions in visceral tissues of Fabry mice
Animal study · Fabry mice (α-galactosidase A knock-out) [2]
Treated Fabry mice received eliglustat tartrate as a component of their food beginning at 5 weeks of age; this formulation provided 300 mg/kg of eliglustat tartrate per day. Treated Fabry mice also continued to accumulate GL-3 throughout the course of the study, but did so at a reduced rate, generally resulting in significant net GL-3 reductions of 40–50% by the end of the study. One exception was the brain, where no difference was seen between treated and untreated mice.
Conditions shared by the study groups
- Route
- as a component of their food
- Treatment course
- beginning at 5 weeks of age
- Vehicle
- standard mouse chow
- Eliglustat 300 mg/kg of eliglustat tartrate per day
- Model: Fabry mice (α-galactosidase A knock-out)
Methods and source locations
Compound reported in the paper: Eliglustat
Evidence for Eliglustat as the tartrate form reported in the paper, not the free base/neutral form supplied as A12386; no salt equivalence, dose conversion or lot validation.
Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Animal Studies > Ethics Statement (S88); Materials and Methods > Treatment regimens (S97, S98); Figure 1 legend (S134, S135)
GL-3 levels in various tissues: GL-3 levels in various tissues; comparator: untreated control Fabry — Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Treatment regimens (S98); Figure 1 legend (S135)
Eliglustat 300 mg/kg of eliglustat tartrate per day · Results > SRT reduces the rate of GL-3 accumulation in visceral tissues (S7, S8, S9); Materials and Methods > Treatment regimens (S98); Figure 1 legend (S134)
Bone parameters in female mice
Animal study · 8-week-old female C57BL/6J mice [3]
8-week-old female C57BL/6J mice received Eliglustat at 150 mg/kg/day in chow for 19 days. Bone parameters, including bone volume over total volume (BV/TV), increased significantly compared with normal chow controls.
Conditions shared by the study groups
- Route
- eliglustat-containing chow
- Treatment course
- for 19 days
- Eliglustat 150 mg/kg/day
- Model: 8-week-old female C57BL/6J mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Eliglustat
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S1, S3); Fig. 1 legend (S303)
bone volume over total volume (BV/TV): bone volume over total volume (BV/TV); comparator: normal chow (Ctr, n = 6 biologically independent animals) — Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S3)
Eliglustat 150 mg/kg/day · Results > Eliglustat increases trabecular bone volume by inhibiting OCs in healthy mice (S1, S3)
Urinary GL-3 response in Fabry mice
Animal study · Fabry mice [2]
Treated Fabry mice received eliglustat tartrate as a component of their food beginning at 5 weeks of age; this formulation provided 300 mg/kg of eliglustat tartrate per day. Treating Fabry mice with eliglustat tartrate (SRT) reduced the urine GL-3 concentration to about 50% that of the untreated mice.
Conditions shared by the study groups
- Route
- as a component of their food
- Treatment course
- beginning at 5 weeks of age
- Vehicle
- standard mouse chow
- Eliglustat 300 mg/kg of eliglustat tartrate per day
- Model: Fabry mice
Methods and source locations
Compound reported in the paper: Eliglustat
Evidence for Eliglustat as the tartrate form reported in the paper, not the free base/neutral form supplied as A12386; no salt equivalence, dose conversion or lot validation.
Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Materials and Methods > Treatment regimens (S97, S98); Figure 2 legend (S138, S139, S141)
Concentration of GL-3 in the urine: Concentration of GL-3 in the urine; comparator: untreated Fabry mice — Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Figure 2 legend (S141)
Eliglustat 300 mg/kg of eliglustat tartrate per day · Results > SRT normalizes urine volume and decreases urine GL-3 levels (S21); Materials and Methods > Treatment regimens (S98); Figure 2 legend (S138)